What Lercanidipine Teva Treats: Main Uses and Benefits

Lercanidipine Teva is commonly used for the management of essential hypertension, which is the medical term for chronically high blood pressure without a specific, identifiable cause. Its primary therapeutic use is relevant for easing the overall symptom load associated with chronic high blood pressure.

This medication is commonly used as a foundational therapy for adult patients diagnosed with mild to moderate elevation of blood pressure. It is generally applied in conditions characterized by sustained vascular stress, often beginning as the sole agent (monotherapy) for initial management, or in combination therapy alongside other antihypertensive drugs. The therapeutic domains relevant for use include conditions presenting with symptoms related to systemic imbalance and those marked by increased physiological stress.

Long-Term Symptomatic Support

A crucial, patient-oriented benefit of Lercanidipine Teva is addressing symptoms related to organ-specific functional stress that can occur without noticeable symptoms. By helping ensure the blood pressure is managed over time, the therapy supports the patient during difficult phases by easing the symptoms related to systemic imbalance.

“The therapy may assist with maintaining functional stability in patients requiring long-term, sustained management of elevated pressure.”

---

Quick Fact: Relief for Systemic Imbalance

Lercanidipine Teva provides supportive relief when symptoms interfere with routine activities, contributing to improved comfort during symptomatic periods.

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults aged 18 years and over.

Populations for whom use is not recommended: Children and adolescents under 18 years of age; use is not recommended during pregnancy or breast-feeding.

Populations for whom use is contraindicated:

• Patients with hypersensitivity to Lercanidipine hydrochloride or any other dihydropyridine.
• Patients with severe hepatic impairment or severe renal impairment ( GFR < 30 ml/min), including those undergoing dialysis.
• Patients with left ventricular outflow tract obstruction, untreated congestive cardiac failure, unstable angina pectoris, or a recent myocardial infarction (within 1 month).
• Women of child-bearing potential who are not using effective contraception.

---

Condition-Specific and Age-Related Rules

Official regulatory documents require special care when commencing treatment in older adults and in patients with mild to moderate renal or hepatic dysfunction. Caution is also required for patients with ischaemic heart disease or sick sinus syndrome (if a pacemaker is not present). Use in children and adolescents is not recommended because the safety and efficacy of the medicine have not been established in this age group.

---

Resulting Eligibility Structure

The eligibility profile strictly limits Lercanidipine Teva to adults free from severe organ dysfunction and specific cardiovascular risk factors. The presence of any absolute contraindication, as defined in the official prescribing information, prohibits the use of this medicine.

Interactions with other medicines and products

Lercanidipine's therapeutic effects and concentrations are significantly influenced by its metabolism through the Cytochrome P450 3A4 (CYP3A4) enzyme system. Combining Lercanidipine with certain substances can lead to interactions that may increase the risk of side effects or reduce the efficacy of treatment.

---

Contraindicated Combinations

The following agents must not be taken with Lercanidipine due to the risk of severe interaction:

• Strong CYP3A4 inhibitors (e.g., Ketoconazole, Itraconazole, Erythromycin, Clarithromycin, Ritonavir), which dramatically increase Lercanidipine exposure.
• Ciclosporin, which increases the plasma levels of both Lercanidipine and Ciclosporin.
• Grapefruit or Grapefruit juice, which increases the drug's systemic availability and hypotensive effect.

---

Significant Interactions Requiring Caution

• CYP3A4 Inducers: Medicines that induce CYP3A4 (e.g., Phenytoin, Carbamazepine, Rifampicin) may decrease Lercanidipine plasma levels, potentially reducing its effectiveness.
• Other Antihypertensive Agents: Co-administration with agents like beta-blockers, diuretics, or alpha-blockers may lead to an additive pharmacodynamic effect, resulting in enhanced blood pressure lowering.
• Alcohol: Consumption of alcohol must be avoided as it potentiates the effect of vasodilating antihypertensive drugs.
• Simvastatin: Lercanidipine increases the exposure of Simvastatin. To mitigate this, administering Lercanidipine in the morning and Simvastatin in the evening is a documented strategy.

---

Other Interactions

Caution is advised when combining Lercanidipine with high doses of Cimetidine or with Digoxin, although the latter has not shown clinically significant pharmacokinetic changes. Patients with hepatic impairment may experience an enhanced antihypertensive effect, warranting consideration of dosage adjustment.

Targeted Blockade of Calcium Channels

Lercanidipine Teva acts as an antagonist of the Voltage-Gated L-type Calcium Channels ( Cav1) located on the smooth muscle cells of peripheral arteries. By physically blocking the flow of calcium ions ( Ca^2+) into these cells, the medication interrupts the essential molecular signal required for muscle contraction. This action is a primary driver of the reduction in resistance throughout the body's circulation.

Modulation of Systemic Vascular Resistance

The resulting cellular relaxation causes widespread vasodilation (widening) of the arteries, leading to a reduction in the overall Systemic Vascular Resistance (SVR). This mechanistic cascade reduces the mechanical opposition (Afterload) the heart encounters, resulting in a decrease in the force exerted against the arterial walls. This physiological consequence reflects the diminished tension across the vascular network.

Influence on Vascular Tone and Duration

The drug's high lipophilicity allows it to partition effectively into the lipid membranes of the vessel walls, sustaining its influence on vascular tone. Lercanidipine Teva's mechanism also affects calcium channels in the small vessels of the kidneys. This modulation of renal hemodynamics occurs through local changes in blood flow dynamics within the kidney's arterioles, which includes the simultaneous dilation of both afferent and efferent arterioles, influencing pressure dynamics and the sustained modulation of peripheral vascular tone.

How to Use Lercanidipine Teva: Official Administration Guidelines

Lercanidipine Teva is strictly administered via the oral route as film-coated tablets. The official administration guidelines define a precise schedule and context for use to maintain consistent management of elevated blood pressure.

---

Standard Dosing and Frequency

The standard initial dose for adults is 10 mg once daily. The maintenance dosage typically ranges from 10 mg to 20 mg once daily, with 20 mg representing the usual maximum recommended daily dose. Lercanidipine Teva is intended for long-term maintenance therapy and is not used for acute episodes.

---

Key Administration Instructions

Administration Scope	Official Instruction
Timing in Relation to Day	Take the tablet once daily in the morning.
Timing in Relation to Meals	Must be taken at least 15 minutes before a meal; avoidance of high-fat meals is specified.
Dose Titration	Any increase from 10 mg should be gradual, allowing approximately two weeks for the full effect of the initial dose to be established.
Missed Dose Rule	If a dose is missed, skip the forgotten dose and take the next dose at the usual time; do not take a double dose to compensate.

---

Population-Specific Usage Rules

Use in the pediatric population (under 18 years) is not recommended due to insufficient data. While no initial dose adjustment is required for older adults or patients with mild to moderate renal or hepatic impairment, treatment initiation and any subsequent dose increase to 20 mg must be approached with caution in these groups.

Research evidence / Overview of Studies for Lercanidipine Teva

Evidence for Use in Essential Hypertension

The research base examined essential hypertension, which is high blood pressure without a clear, identifiable cause. This area was evaluated through a substantial foundation of Randomized Controlled Trials (RCTs) and studies that compared the drug against an inactive treatment (placebo). Research examined key physiological outcomes, primarily in studies that monitored changes in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) in the clinic.

Studies also explored patterns related to changes in blood pressure levels in the observed populations during the study period. Studies monitored patterns related to blood pressure stabilization and focused on measurements of stability over the study period.

Further data show patterns related to blood pressure evolution over a full 24-hour cycle, which was evaluated using specialized Ambulatory Blood Pressure Monitoring (ABPM). Studies describe what has been observed so far when this medication was studied as a single agent or in combination with other blood pressure medicines.

Comparing Research Against Other Medications

Studies also explored how Lercanidipine Teva was evaluated in relation to other established medications. This involved Active-Controlled Comparator Studies where research examined the drug alongside other widely used types of blood pressure agents. Findings indicate patterns observed in these studies regarding blood pressure changes. These comparison studies contribute to the broader evidence landscape by providing context on the measurements obtained when compared to the other medications used in the research.

Long-Term Studies and Durability of Response

Studies have explored the sustained effects of Lercanidipine Teva over defined time intervals. While the core trials establishing initial patterns of use were short-term (typically lasting less than 16 weeks), research has also been conducted using Long-term Open-label Extension Studies and observational settings evaluating daily-life functioning. These studies explored measurements of blood pressure stability over periods of a year and, in some cases, for up to three years.

Findings describe patterns observed in these extended studies, which contribute to understanding the measurements of blood pressure stability over time. Additionally, large-scale observational research has explored long-term outcomes by monitoring cardiovascular events. However, long-term effects are not fully established through the same depth of randomized, placebo-controlled trials as the short-term blood pressure control measurements.

Evidence in Specific Patient Populations

Research examined the use of this medication in several important patient subgroups. Studies were conducted in Older Adults (some including patients up to 85 years of age) to assess whether similar patterns of blood pressure change were observed compared to younger adult populations. Research has also examined the use of this medication in patients with Type 2 Diabetes Mellitus, where studies monitored physiological strain or stress by looking at markers of kidney function.

Some studies examined patients with mild markers of renal impairment. Studies report patterns of symptoms observed in the populations where comorbidities were present. However, the initial randomized trials often excluded patients with severe co-existing conditions, meaning data for certain complex groups remain insufficient.

Key Limitations and Areas of Uncertainty

Research provides context, but evidence highlights what is known and what is still uncertain. Follow-up durations were limited in many of the initial, strictly controlled trials, particularly those using a placebo. Subgroup findings are uncertain or based on limited information, especially for patients with significant cardiovascular or liver disease, as these individuals were typically not included in the primary clinical trials.

The evidence quality varies across studies, with some older research included in meta-analyses having limited information for reporting methodological details like blinding. Results apply only to the populations studied under the specific conditions of the clinical research, and comparative evidence for long-term clinical endpoints is limited. Research is ongoing to further contribute to the broader evidence landscape.

Common questions about Lercanidipine Teva (FAQ)

---

Q: Is it better to take Lercanidipine Teva with food or on an empty stomach?

Official administration instructions indicate that the tablets are to be taken at least 15 minutes before a meal. Consumption with high-fat meals is specified for avoidance, as this can affect how the drug is absorbed by the body. The official product information stresses the importance of following this required timing.

---

Q: What does Lercanidipine Teva do to the blood vessels to lower blood pressure?

Lercanidipine Teva is a type of medicine known as a calcium channel blocker. The official information states that its main action is as a peripheral vasodilator. This means the drug works by causing the small arteries to widen or relax, which lowers the overall resistance in the blood vessels and helps to reduce high blood pressure.

---

Q: How long will I have to take this medication?

According to the official product information, Lercanidipine Teva is indicated for the treatment of high blood pressure and is intended for long-term maintenance therapy. The actual duration of treatment is determined by the patient's healthcare provider based on their specific clinical needs and response.

---

Q: Can Lercanidipine Teva be safely stopped once my blood pressure is normal?

Regulatory guidance states that consultation with a healthcare professional is necessary before stopping the treatment. Stopping this medication abruptly, even if blood pressure has stabilized, may lead to an increase in blood pressure again.

---

Q: What should I do if my blood pressure remains high after starting this drug?

Official documents note that the maximal antihypertensive effect of an initial dose may take about two weeks to become fully apparent. Any adjustments or changes to the dosage regimen are determined by a qualified healthcare professional based on ongoing blood pressure monitoring and assessment.

---

Q: Does this medicine cause weight gain?

Adverse reactions in the official safety profile for Lercanidipine Teva are classified by their observed frequency. Weight gain is not listed among the common, uncommon, or rare side effects reported in this profile.

---

Q: Does this blood pressure medicine come in a liquid form or only as tablets?

The official regulatory documents consistently describe Lercanidipine Teva as 'film-coated tablets' for oral use. No other forms, such as a liquid, are typically listed in the product’s official pharmaceutical form section.

How to Store and Dispose of Lercanidipine Teva

Lercanidipine Teva must be stored according to official regulatory labeling to maintain product stability and safety. The medicine must be kept out of the sight and reach of children.

---

Storage Requirements

• Temperature and Protection: Storage requirements vary; some official sources state store below 25°C, while others indicate no special temperature storage conditions are required. The product must be kept in the original package for protection from light and moisture.
• Stability: Do not use the medicine after the stated expiry date. For specific bottle presentations, the product must be discarded 30 days after first opening.

---

Disposal Instructions

Disposal must adhere strictly to local regulations. Regulatory documents explicitly state do not throw away any unused or expired Lercanidipine Teva via wastewater or household waste. The product must be disposed of in accordance with local requirements by consulting a pharmacist.